PDCD1 and melanoma: Peptide neoantigen vaccines targeting DCs by subcutaneous injection and activating T cells within LNs have shown significant antitumor effects in melanoma patients, with emerging evidence of synergistic efficacy when combined with PD-1 inhibitors[136].